Wednesday, July 8, 2026

pharma · Covid-19 · Chronic Myocardial Ischemia · LSTA

Lisata Therapeutics

Lisata Therapeutics clinical programs — 15 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

110 Allen Road, 2nd Flr, Basking Ridge, NJ 07920, US HQ
2006 Founded
38 Employees
Public company Type
LSTA · NYSE Ticker
Company details
Status
Public
HQ
110 Allen Road, 2nd Flr, Basking Ridge, NJ 07920, US
Founded
2006
Employees
38
Programs
15
Drugs
13
Patents
1
Intelligence · Clinical Programs

Lisata Therapeutics projects

15 ClinicalTrials.gov programs sponsored by Lisata Therapeutics.

Lisata Therapeutics has 15 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Auto-CD34+ cells

    LISATA THERAPEUTICS, INC.

    Chronic Myocardial Ischemia

    phase 3 mab completed

    1 trial
  2. Autologous Dendritic Cell-Tumor Cell Immunotherapy (DC-TC)

    LISATA THERAPEUTICS, INC.

    Stage IV Melanoma

    phase 3 mab terminated

    1 trial
  3. CLBS03 Low Dose

    LISATA THERAPEUTICS, INC.

    Diabetes Mellitus

    phase 2 mab completed

    1 trial
  4. CLBS12

    LISATA THERAPEUTICS, INC.

    Critical Limb Ischemia

    phase 2 mab completed

    1 trial
  5. CLBS14 (low-dose)

    LISATA THERAPEUTICS, INC.

    Myocardial Ischemia

    phase 2 mab completed

    1 trial
  6. CLBS16

    LISATA THERAPEUTICS, INC.

    Coronary Microvascular Dysfunction

    phase 2 mab terminated

    2 trials
  7. NBS10

    LISATA THERAPEUTICS, INC.

    ST Segment Elevation Myocardial Infarction

    phase 2 mab completed

    1 trial
  8. certepetide

    LISATA THERAPEUTICS, INC.

    Pancreas Cancer

    phase 2 small molecule terminated

    1 trial
  9. certepetide

    LISATA THERAPEUTICS, INC.

    Cholangiocarcinoma

    phase 2 small molecule active

    1 trial
  10. lymphokine-activated killer cells

    LISATA THERAPEUTICS, INC.

    Brain and Central Nervous System Tumors

    phase 2 mab terminated

    1 trial
  11. therapeutic autologous dendritic cells

    LISATA THERAPEUTICS, INC.

    Melanoma (Skin)

    phase 2 mab completed

    1 trial
  12. Biological/Vaccine: therapeutic autologous dendritic cells.

    LISATA THERAPEUTICS, INC.

    Kidney Cancer

    phase 1 mab terminated

    1 trial
  13. CEND-1

    LISATA THERAPEUTICS, INC.

    Pancreatic Cancer

    phase 1 small molecule completed

    1 trial
  14. CLBS119

    LISATA THERAPEUTICS, INC.

    Covid-19

    phase 1 mab terminated

    1 trial
  15. CLBS201

    LISATA THERAPEUTICS, INC.

    Chronic Kidney Diseases

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Lisata Therapeutics have?

15 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.